Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics plc (Nasdaq: AUTL) generates frequent news as an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies for cancer and autoimmune disease. News coverage for AUTL often centers on AUCATZYL® (obecabtagene autoleucel; obe-cel), the company’s CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and on the clinical and commercial progress of this product.
Investors and healthcare observers following Autolus news will see updates on AUCATZYL net product revenue, treatment center activation, and reimbursement developments such as NICE recommendations and conditional marketing authorizations in the UK and EU. Press releases also describe real-world data from consortia like ROCCA, which evaluate safety and response rates for AUCATZYL in clinical practice, alongside analyses from the FELIX study that explore CAR T-cell persistence and product cell phenotypes as potential predictors of long-term outcomes.
Autolus regularly reports clinical data from its broader pipeline, including the CATULUS trial in pediatric relapsed or refractory B-ALL, the CARLYSLE Phase 1 study in severe refractory systemic lupus erythematosus, the LUMINA Phase 2 trial in lupus nephritis and the BOBCAT trial in progressive multiple sclerosis. These updates typically highlight remission rates, safety profiles, B-cell depletion and immune reset signals in autoimmune indications. Additional news items cover collaborations, such as the evaluation of Cellares’ automated Cell Shuttle platform to support high-throughput CAR T manufacturing, and corporate developments including leadership appointments and participation in healthcare conferences.
This news page allows readers to track Autolus’ ongoing clinical milestones, regulatory and reimbursement decisions, manufacturing initiatives and financial disclosures related to its T cell therapy programs. For those monitoring AUTL, the flow of updates provides context on how AUCATZYL and pipeline candidates are progressing across hematologic malignancies, solid tumors and autoimmune diseases.
Autolus Therapeutics (NASDAQ: AUTL) announced insights from a Nature Cancer publication on the durability of acute lymphoblastic leukemia (ALL) treatments using AUTO1. The findings reveal that long-term response in pediatric ALL patients correlates with an enrichment of Stem Cell Memory T cells (TSCM). These TSCM cells are believed to support sustained immune response. AUTO1's design encourages efficient targeting and minimized T cell exhaustion, enhancing its therapeutic potential. The investigational therapy is being evaluated in ongoing clinical trials.
Autolus Therapeutics (Nasdaq: AUTL) announced its Annual General Meeting (AGM) scheduled for June 18, 2021, at its headquarters in White City, London. Due to COVID-19 restrictions, in-person attendance is prohibited, and a minimum quorum of two shareholders is required. Shareholders are encouraged to submit proxy votes ahead of the meeting as voting during the AGM will not be possible. No webcast will be provided this year, and results will be announced via press release afterwards.
Autolus Therapeutics plc (Nasdaq: AUTL) announced a 100% complete remission rate in a cohort of patients with relapsed/refractory indolent B cell lymphomas (IBCL) treated with its investigational therapy, AUTO1. The early results were presented at the European Hematology Association Virtual Congress on June 9-17, 2021. Of the 10 patients treated, 9 were evaluable, and 8 remain in ongoing remission at a median of 3.1 months. Importantly, no high-grade cytokine release syndrome or neurotoxicity was observed, indicating a favorable safety profile for AUTO1.
Autolus Therapeutics (Nasdaq: AUTL) reported Q1 2021 results, showing a net loss of $33.3 million or $(0.53) per share. Cash reserves amounted to $239 million, up from $153.3 million at year-end 2020. The company is focusing on its AUTO1 program, with upcoming data expected in 2022 from pivotal studies. The firm also received PRIME designation for AUTO1 in the EU, and innovative licensing for AUTO4 in PTCL. Operational changes aim to save $15 million annually. A follow-on public offering generated $106.9 million in February 2021. Management expects cash runway to last into H1 2023.
Autolus Therapeutics plc (Nasdaq: AUTL) announced it will release its Q1 2021 financial results and operational highlights on May 6, 2021, before U.S. market open. Management will host a conference call at 8:30 am ET to discuss these results and provide a business update. Interested parties can access the webcast on Autolus' website or dial in via provided numbers. A replay of the call will be available post-event.
Autolus Therapeutics plc (Nasdaq: AUTL) has received the Innovative Licensing and Access Pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for AUTO4, a product in Phase 1 trials for TRBC1 positive Peripheral T Cell Lymphoma (PTCL). This designation follows the PRIME designation received for AUTO1, aimed at accelerating the review of therapies addressing unmet medical needs. The ILAP facilitates enhanced dialogue with regulators and access to development tools, potentially leading to faster patient access in the UK.
Autolus Therapeutics plc (Nasdaq: AUTL) appointed Dr. Martin Murphy as non-executive chairman of its Board of Directors, effective April 15, 2021. This change follows Dr. Christian Itin's long tenure as chairman and CEO since the company's inception in 2014. The separation of these roles aims to enhance leadership focus as the lead program, AUTO1, progresses through clinical trials and gears up for potential commercialization. Dr. Murphy brings over 25 years of life sciences experience, previously serving as a non-executive director since 2014.
Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in several investor conferences throughout April 2021. Key events include the Wells Fargo Annual Biotech Corporate Access on April 6 and 8, and the 20th Annual Needham Virtual Healthcare Conference on April 14, where the CEO and CFO will engage in a Fireside Chat. Additionally, Autolus will partake in the Raymond James Oncology Summit on April 22 and Kempen & Co. European Life Sciences: Gene, Cell, and RNA Day on April 28. This participation highlights Autolus's commitment to advancing its next-generation T cell therapies for cancer treatment.
Autolus Therapeutics (Nasdaq: AUTL) has received PRIME designation from the European Medicines Agency for its CAR T cell therapy AUTO1, aimed at treating relapsed/refractory adult B-acute lymphocytic leukemia. This designation enhances support for development and review, potentially expediting access to patients with unmet medical needs. AUTO1 showcases promising activity and safety data, with ongoing studies evaluating its effectiveness. The FELIX study will enroll 100 patients to assess overall response rate and safety, positioning AUTO1 as a potential game-changer in treating this condition.
Autolus Therapeutics plc (Nasdaq: AUTL) has announced a strategic shift in its manufacturing operations for AUTO1, moving to a more cost-effective commercial supply strategy based in the UK. This change will utilize existing facilities and a new site to enhance its operational capacity. Additionally, the company has mutually terminated its lease in Rockville, MD, resulting in a cash payment and the cessation of lease obligations, which aims to further reduce costs.
FAQ
What is the current stock price of AUTOLUS THERAPEUTICS PLC (AUTL)?
What is the market cap of AUTOLUS THERAPEUTICS PLC (AUTL)?
